Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts

Cancer Research

Volumn 61, Issue 21, 2001, Pages 8005-8013

  Deininger, Michael W N ^a,b   Vieira, Sara A D ^a   Parada, Yelena ^c   Banerji, Lolita ^c   Lam, Eric W F ^c   Peters, Gordon ^d   Mahon, François Xavier ^a   Köhler, Thomas ^e   Goldman, John M ^a   Melo, Junia V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e Roboscreen Gesellschaft Für Molekulare Biotechnologie Mbh   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN D2; HYBRID PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME ACTIVITY; FUSION GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; LYMPHOBLAST; MALIGNANT TRANSFORMATION; MITOSIS INHIBITION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLAST CRISIS; CYCLINS; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; G1 PHASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LYMPHOCYTES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; S PHASE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0035503069     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results
2. Expression of a distinctive BCR-ABL oncogene in Phl-positive acute lymphocytic leukemia (ALL)
3. Abl tyrosine protein kinase
4. Cycling, stressed-out and nervous: Cellular functions of c-Abl
5. l-to-S phase transition in hematopoietic cells
6. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
7. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages
8. 1 checkpoint
9. Differential control of cyclins D1 and D3 and the cdk inhibitor p27Kipl by diverse signalling pathways in Swiss 3T3 cells
10. What is the restriction point?
11. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
12. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia
13. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
14. A novel cyclin encoded by a bcll-linked candidate oncogene
15. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining
16. The cyclin D1 gene is a target of the β-catenin/LEF-I pathway
17. The cytogenetic theory of the pathogenesis of human adult male germ cell tumors. Review article
18. Overexpression of cyclin D2 in chronic B-cell malignancies
19. Cyclin D2 but not cyclin DI, overexpression closely correlates with gastric cancer progression and prognosis
20. Signaling by, ABL oncogenes through cyclin D1
21. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
22. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells
23. The MAP kinase inhibitors, PD098059. UO126 and SB203580. inhibit IL-1βdependent PGE(2) release via mechanistically distinct processes
24. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
25. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells
26. Rescue of defective mitogenic signaling by D-type cyclins
27. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helperfree packaging cell line
28. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
29. 1 phase progression in specific cell types
30. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells
31. BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte -macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia
32. p190 BCR-ABL mRNA is expressed at low levels in p210 -positive chronic myeloid and acute lymphoblastic leukemias
33. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma
34. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia
35. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon
36. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
37. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)
38. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines
39. Opposite regulation of the expression of cyclin-dependent kinase inhibitors during contact inhibition
40. Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells
41. Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes
42. 1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation
43. Cyclin D3 regulates proliferation and apoptosis of leukemic T cell lines
44. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2, and p27Kipl expression
45. Anti-sense oligodeoxynucleotides-promises and pitfalls
46. Nucleic acid therapeutics: State of the art and future prospects
47. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes
48. 1 cell cycle stage following delivery of complete versus partial activation stimuli
49. Regulation of the catalytic subunit (p34PSK-J3/cdk4) for the major D-type cyclin in mature B lymphocytes
50. 2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest
51. Phosphatidylinositol 3-kinase and NF-kB/Rel are at the divergence of CD40-mediated proliferation and survival pathways
52. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
53. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization
54. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors
55. Establishment of a lymphoblastoid cell line, SD-1, expressing the p190 bcr-abl chimaeric protein
56. 0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus
57. Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene